INHALE-1—Inhaled Insulin in Pediatric Diabetes

Michael J. Haller, MD

Professor and Chief, Pediatric Endocrinology,

University of Florida

What is your presentation about?
We will present data from the large randomized controlled trial seeking to document the non-inferiority of inhaled insulin vs. rapid acting analogue insulin in children with diabetes. The study presentation will provide safety and efficacy for inhaled insulin in children and discuss future plans for inhaled insulin as an important option for managing diabetes in children.

How do you hope your presentation will impact diabetes research or care?
We will ensure clarity on the safety and efficacy of inhaled insulin in children and hope to see this therapy reach U.S. Food and Drug Administration approval in children and provide additional tools for management for people of all ages living with diabetes.

How did you become involved with this area of diabetes research or care?
I am the principal investigator of the national study and have been working with inhaled insulin for more than 10 years.

---

Adjunctive Medical Therapy using SGLT2i for Youth with Type 1 Diabetes

Farid H. Mahmud, MD

Clinician Investigator,

Hospital For Sick Children

What is your presentation about?
This presentation describes the key results from ATTEMPT (The Adolescent Type 1 Diabetes Treatment with SGLT2i for Hyperglycemia & Hyperfiltration Trial), which showed that low-dose sodium-glucose cotransporter-2 (SGLT2) inhibitors could safely be given to youth and adolescents with type 1 diabetes to improve kidney function and glycemic management. ATTEMPT is the first-of-its-kind trial designed to evaluate the effectiveness of SGLT2 inhibitors to optimize diabetes management and prevent early subclinical kidney complications in youth with type 1 diabetes.

ATTEMPT is a double-blinded, randomized, placebo-controlled trial that evaluated the impact of the SGLT2 inhibitor dapagliflozin on key physiologic, mechanistic, and metabolic outcomes when using SGLT2 inhibitors alongside insulin in type 1 diabetes.

How do you hope your presentation will impact diabetes research or care?
The presentation is designed to share high-quality data, as well as patient perspectives, on adjunct-to-insulin treatments that impact kidney disease progression and optimize diabetes management in adolescents and young adults during a challenging period associated with above-target A1C, alongside approaches to monitor and mitigate the potential risks of ketosis that may be present.

How did you become involved with this area of diabetes research or care?
My motivation stems from my clinical experiences in caring for adolescents and their families living with diabetes. They deserve high-quality pediatric studies to evaluate new treatment options to delay or prevent disease progression and address the challenges of elevated A1C and weight management often seen during this critical developmental period.